Navigation Links
Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence

Aromatase Inhibitors drug, Femara given after 5 years of Tamoxifen therapy is found to give protection against occurrence of Breast cancer recurrence. Breast cancer is the second leading cause of cancer// in women. Breast cancer mostly occurs in post menopausal women and various risk factors are attributed for the occurrence of breast cancer.

Treatment of breast cancer initially involves removal of the entire breast or part of the breast with the cancer lump followed by Radiation therapy and Chemotherapy. Cytotoxic drugs are given as chemotherapy for patients with breast cancer; usually 6 cycles of chemotherapeutic drugs are given such as Cyclophosphamide, 5 flurouracil, adiramycin. After these procedures 5 years of Tamoxifen therapy is recommended for post menopausal women. Tamoxifen therapy is recommended only for 5 years as studies in which tamoxifen given for more than 5 years shows no difference. Tamoxifen acts as an anti-estrogen by which it competitively inhibits the estrogens produced by the body, as estrogen is used up by the cancer cell for its growth and production. Metastasis and recurrence occurs in some cancer patients, though the chance of metastasis is very less as only 1 in 10000 cells has the capacity to reach the blood stream and cause cancer in a new organ.

Recurrence mostly occurs due to pitfalls or not properly taking therapy or tablets, even tamoxifen resistance developed by the patient may also lead to recurrence. Recurrence may occur at the same initial cancer site called as loco-regional or in a new site.

The new study using Femara Aromatase Inhibitors after 5 years of Tamoxifen therapy as found to give protection against occurrence of recurrence. Aromatase inhibitors lower the levels of estrogen in the body by acting on the Aromatase enzyme involved in making estrogen. The study was conducted in 5000 postmenopausal women who have finished their 5 years tamoxifen therapy and they were given femara for an other 5 years. Though the overall survival rates of both the group were same, the group taking femara had a significant lower risk of breast cancer recurrence. The patients with lymph node positive cancer had a significant better survival rate taking femara. Though femara had some side effects such as osteoporosis in 8.1 %, hot flashes in 58 % and hair loss, and these side effects are very common and less significant compared to its benefits.
'"/>




Related medicine news :

1. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. LipB Protein Inhibitors Help To Fight Against TB
4. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Thyroid hormone treatment hastens recovery after cardiac surgery
9. Morning after pill effective up to five days after having unprotected sex
10. Liver donors can thrive after transplant
11. Recouping blood flow after a stroke
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: